Drake & Associates LLC Has $1.22 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Drake & Associates LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 10.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,379 shares of the company’s stock after acquiring an additional 133 shares during the period. Eli Lilly and Company comprises approximately 0.4% of Drake & Associates LLC’s portfolio, making the stock its 23rd largest position. Drake & Associates LLC’s holdings in Eli Lilly and Company were worth $1,222,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Secure Asset Management LLC grew its holdings in shares of Eli Lilly and Company by 18.2% in the 3rd quarter. Secure Asset Management LLC now owns 1,956 shares of the company’s stock valued at $1,733,000 after buying an additional 301 shares during the period. Trifecta Capital Advisors LLC grew its holdings in shares of Eli Lilly and Company by 0.6% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 21,947 shares of the company’s stock valued at $19,444,000 after buying an additional 131 shares during the period. LifeSteps Financial Inc. grew its holdings in shares of Eli Lilly and Company by 20.1% in the 3rd quarter. LifeSteps Financial Inc. now owns 359 shares of the company’s stock valued at $318,000 after buying an additional 60 shares during the period. Global Retirement Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.0% in the 3rd quarter. Global Retirement Partners LLC now owns 18,983 shares of the company’s stock valued at $16,818,000 after buying an additional 380 shares during the period. Finally, Good Life Advisors LLC boosted its stake in Eli Lilly and Company by 14.4% in the 3rd quarter. Good Life Advisors LLC now owns 2,973 shares of the company’s stock worth $2,635,000 after purchasing an additional 374 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.1 %

Shares of LLY stock opened at $917.18 on Friday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm’s 50-day moving average is $920.70 and its 200-day moving average is $856.27. The stock has a market cap of $871.69 billion, a price-to-earnings ratio of 135.08, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Sell-side analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on LLY. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday. They issued an “outperform” rating and a $1,100.00 target price for the company. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Finally, Bank of America upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.